Safety of Daiobotampito in the Treatment of Acute Diverticulitis of the Colon

A Single-Center, Open-Label, Prospective Trial

Hiroshi Koike, Atsushi Nakazawa, Yuko Horiba, Nobuhiro Tsukada, Kenji Watanabe

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to investigate the safety of daiobotampito in the treatment of acute diverticulitis of the colon. Methods: We conducted a single-center, open-label, prospective study. Ten patients who suffered from diverticulitis of the colon were recruited. The patients were treated with fasting, antibacterial agents, and daiobotampito extract for 10 days in or out of hospital. The patients individually recorded their body temperature, grade of abdominal pain, number of times that analgesics were used, and number of stools daily. We checked whether the patients had adverse reactions such as abdominal pain or diarrhea. Results: No patients experienced serious adverse reactions. One patient had moderate abdominal pain and diarrhea soon after daiobotampito intake. This patient discontinued daiobotampito on day 4, and the pain and diarrhea quickly resolved. The abdominal pain of this patient was worse 6 days before treatment, and the pain was almost relieved with initial daiobotampito treatment. Conclusions: Daiobotampito is a safe treatment option for early stage, acute diverticulitis.

Original languageEnglish
Pages (from-to)885-889
Number of pages5
JournalJournal of Alternative and Complementary Medicine
Volume23
Issue number11
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Diverticulitis
Colon
Safety
Abdominal Pain
Diarrhea
Therapeutics
Pain
Body Temperature
Analgesics
Fasting
Prospective Studies
Anti-Bacterial Agents

Keywords

  • daiobotampito
  • Kampo medicine
  • phase II trial
  • safety

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

Safety of Daiobotampito in the Treatment of Acute Diverticulitis of the Colon : A Single-Center, Open-Label, Prospective Trial. / Koike, Hiroshi; Nakazawa, Atsushi; Horiba, Yuko; Tsukada, Nobuhiro; Watanabe, Kenji.

In: Journal of Alternative and Complementary Medicine, Vol. 23, No. 11, 01.11.2017, p. 885-889.

Research output: Contribution to journalArticle

@article{f2907456b079458292b3ef4dfe32989b,
title = "Safety of Daiobotampito in the Treatment of Acute Diverticulitis of the Colon: A Single-Center, Open-Label, Prospective Trial",
abstract = "Purpose: The purpose of this study was to investigate the safety of daiobotampito in the treatment of acute diverticulitis of the colon. Methods: We conducted a single-center, open-label, prospective study. Ten patients who suffered from diverticulitis of the colon were recruited. The patients were treated with fasting, antibacterial agents, and daiobotampito extract for 10 days in or out of hospital. The patients individually recorded their body temperature, grade of abdominal pain, number of times that analgesics were used, and number of stools daily. We checked whether the patients had adverse reactions such as abdominal pain or diarrhea. Results: No patients experienced serious adverse reactions. One patient had moderate abdominal pain and diarrhea soon after daiobotampito intake. This patient discontinued daiobotampito on day 4, and the pain and diarrhea quickly resolved. The abdominal pain of this patient was worse 6 days before treatment, and the pain was almost relieved with initial daiobotampito treatment. Conclusions: Daiobotampito is a safe treatment option for early stage, acute diverticulitis.",
keywords = "daiobotampito, Kampo medicine, phase II trial, safety",
author = "Hiroshi Koike and Atsushi Nakazawa and Yuko Horiba and Nobuhiro Tsukada and Kenji Watanabe",
year = "2017",
month = "11",
day = "1",
doi = "10.1089/acm.2016.0367",
language = "English",
volume = "23",
pages = "885--889",
journal = "Journal of Alternative and Complementary Medicine",
issn = "1075-5535",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Safety of Daiobotampito in the Treatment of Acute Diverticulitis of the Colon

T2 - A Single-Center, Open-Label, Prospective Trial

AU - Koike, Hiroshi

AU - Nakazawa, Atsushi

AU - Horiba, Yuko

AU - Tsukada, Nobuhiro

AU - Watanabe, Kenji

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose: The purpose of this study was to investigate the safety of daiobotampito in the treatment of acute diverticulitis of the colon. Methods: We conducted a single-center, open-label, prospective study. Ten patients who suffered from diverticulitis of the colon were recruited. The patients were treated with fasting, antibacterial agents, and daiobotampito extract for 10 days in or out of hospital. The patients individually recorded their body temperature, grade of abdominal pain, number of times that analgesics were used, and number of stools daily. We checked whether the patients had adverse reactions such as abdominal pain or diarrhea. Results: No patients experienced serious adverse reactions. One patient had moderate abdominal pain and diarrhea soon after daiobotampito intake. This patient discontinued daiobotampito on day 4, and the pain and diarrhea quickly resolved. The abdominal pain of this patient was worse 6 days before treatment, and the pain was almost relieved with initial daiobotampito treatment. Conclusions: Daiobotampito is a safe treatment option for early stage, acute diverticulitis.

AB - Purpose: The purpose of this study was to investigate the safety of daiobotampito in the treatment of acute diverticulitis of the colon. Methods: We conducted a single-center, open-label, prospective study. Ten patients who suffered from diverticulitis of the colon were recruited. The patients were treated with fasting, antibacterial agents, and daiobotampito extract for 10 days in or out of hospital. The patients individually recorded their body temperature, grade of abdominal pain, number of times that analgesics were used, and number of stools daily. We checked whether the patients had adverse reactions such as abdominal pain or diarrhea. Results: No patients experienced serious adverse reactions. One patient had moderate abdominal pain and diarrhea soon after daiobotampito intake. This patient discontinued daiobotampito on day 4, and the pain and diarrhea quickly resolved. The abdominal pain of this patient was worse 6 days before treatment, and the pain was almost relieved with initial daiobotampito treatment. Conclusions: Daiobotampito is a safe treatment option for early stage, acute diverticulitis.

KW - daiobotampito

KW - Kampo medicine

KW - phase II trial

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85034588530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034588530&partnerID=8YFLogxK

U2 - 10.1089/acm.2016.0367

DO - 10.1089/acm.2016.0367

M3 - Article

VL - 23

SP - 885

EP - 889

JO - Journal of Alternative and Complementary Medicine

JF - Journal of Alternative and Complementary Medicine

SN - 1075-5535

IS - 11

ER -